MX2016009385A - Inhibidores macrociclicos del factor xia condensados con heterociclicos. - Google Patents
Inhibidores macrociclicos del factor xia condensados con heterociclicos.Info
- Publication number
- MX2016009385A MX2016009385A MX2016009385A MX2016009385A MX2016009385A MX 2016009385 A MX2016009385 A MX 2016009385A MX 2016009385 A MX2016009385 A MX 2016009385A MX 2016009385 A MX2016009385 A MX 2016009385A MX 2016009385 A MX2016009385 A MX 2016009385A
- Authority
- MX
- Mexico
- Prior art keywords
- factor xia
- heterocycles
- condensed
- xia inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula (Ia) (ver Fórmula) o estereoisómeros, tautómeros o sales de los mismos aceptables desde el punto de vista farmacéutico, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores selectivos del factor XIa o inhibidores duales de FXIa y calicreína plasmática. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y a métodos para tratar trastornos tromboembólicos y/o inflamatorios mediante su uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461933948P | 2014-01-31 | 2014-01-31 | |
PCT/US2015/013647 WO2015116882A1 (en) | 2014-01-31 | 2015-01-30 | Macrocyclic factor xia inhibitors condensed with heterocycles |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009385A true MX2016009385A (es) | 2016-09-16 |
Family
ID=52484569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009385A MX2016009385A (es) | 2014-01-31 | 2015-01-30 | Inhibidores macrociclicos del factor xia condensados con heterociclicos. |
Country Status (23)
Country | Link |
---|---|
US (3) | US20170057961A1 (es) |
EP (1) | EP3099688B1 (es) |
JP (1) | JP6419836B2 (es) |
CN (1) | CN106459051B (es) |
AR (1) | AR099228A1 (es) |
BR (1) | BR112016016741B1 (es) |
CA (1) | CA2937738C (es) |
CY (1) | CY1120534T1 (es) |
DK (1) | DK3099688T3 (es) |
EA (1) | EA032650B1 (es) |
ES (1) | ES2655540T3 (es) |
HR (1) | HRP20172002T1 (es) |
HU (1) | HUE038060T2 (es) |
LT (1) | LT3099688T (es) |
MX (1) | MX2016009385A (es) |
NO (1) | NO2760821T3 (es) |
PL (1) | PL3099688T3 (es) |
PT (1) | PT3099688T (es) |
RS (1) | RS56785B1 (es) |
SI (1) | SI3099688T1 (es) |
TW (1) | TWI703144B (es) |
UY (1) | UY35972A (es) |
WO (1) | WO2015116882A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2766346T3 (pl) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
HUE040226T2 (hu) | 2014-01-31 | 2019-02-28 | Bristol Myers Squibb Co | Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként |
NO2760821T3 (es) | 2014-01-31 | 2018-03-10 | ||
WO2016036893A1 (en) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
NO2721243T3 (es) * | 2014-10-01 | 2018-10-20 | ||
EP3310777B1 (en) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
ES2803659T3 (es) | 2015-07-29 | 2021-01-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor xia que contienen restos alquilo o cicloalquilo p2 |
ES2937156T3 (es) | 2015-07-29 | 2023-03-24 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que llevan un grupo P2' no aromático |
AU2016344476B2 (en) * | 2015-10-29 | 2020-08-13 | Merck Sharp & Dohme Llc | Factor XIa inhibitors |
EP3371162B1 (en) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
EP3423458A1 (en) | 2016-03-02 | 2019-01-09 | Bristol-Myers Squibb Company | Diamide macrocycles having factor xia inhibiting activity |
US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
US10765116B2 (en) | 2016-11-23 | 2020-09-08 | Bayer Cropscience Aktiengesellschaft | 2-[3-(alkylsulfonyl)-2H-indazol-2-yl]-3H-imidazo[4,5-B]pyridine derivatives and similar compounds as pesticides |
KR102628073B1 (ko) | 2017-01-10 | 2024-01-22 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
UY37556A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
CN110922412A (zh) * | 2018-09-20 | 2020-03-27 | 复旦大学 | 具有抗精神病作用药物化合物的不对称合成方法 |
WO2020211781A1 (zh) * | 2019-04-16 | 2020-10-22 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
US20220281868A1 (en) * | 2019-07-23 | 2022-09-08 | Medshine Discovery Inc. | Macrocyclic derivatives as factor xia inhibitors |
CN115215867B (zh) * | 2021-04-21 | 2023-12-26 | 上海美悦生物科技发展有限公司 | FXIa抑制剂及其药物组合物、制备方法和用途 |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507597A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼ阻害剤 |
PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
PT1064298E (pt) | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inibidores de caspasas |
AU763839B2 (en) | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
KR20010101355A (ko) | 1999-01-02 | 2001-11-14 | 로버트 흐라이탁, 미쉘 베스트 | 신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 xa 활성 억제) |
EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
HUP0203167A3 (en) | 1999-04-09 | 2003-09-29 | Basf Ag | Peptidic substances, their preparations and their use as complement protease inhibitors |
WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
WO2003011222A2 (en) | 2001-07-27 | 2003-02-13 | Merck & Co., Inc. | Thrombin inhibitors |
US6951840B2 (en) | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
CH1427415H1 (de) | 2001-09-21 | 2023-12-21 | Bristol Myers Squibb Holdings Ireland | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
WO2003041641A2 (en) | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
WO2003106438A1 (en) | 2002-06-18 | 2003-12-24 | The Scripps Research Institute | Synthesis of diazonamide "a" core |
US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ,インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
WO2006017295A2 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
WO2006076575A2 (en) | 2005-01-13 | 2006-07-20 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
WO2007047608A2 (en) | 2005-10-14 | 2007-04-26 | Epix Pharmaceuticals, Inc. | Fibrin targeted therapeutics |
CN101304989A (zh) | 2005-11-11 | 2008-11-12 | 弗·哈夫曼-拉罗切有限公司 | 作为凝血因子xa抑制剂的碳环稠合环胺 |
US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
KR20080087817A (ko) | 2005-12-14 | 2008-10-01 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 xia 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체 |
TW200745062A (en) | 2005-12-23 | 2007-12-16 | Bristol Myers Squibb Co | Macrocyclic factor VIIA inhibitors useful as anticoagulants |
EP2102189B1 (en) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
AR067329A1 (es) | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
TWI577665B (zh) * | 2010-02-11 | 2017-04-11 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之巨環類 |
EP2729150B1 (en) | 2011-07-08 | 2016-09-14 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
PL2766346T3 (pl) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA |
ES2699226T3 (es) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
CN103987696B (zh) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
EP3290413B9 (en) | 2011-12-21 | 2020-04-29 | ONO Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
LT2847228T (lt) | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas |
GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
TW201416362A (zh) | 2012-07-19 | 2014-05-01 | Dainippon Sumitomo Pharma Co | 1-(環烷基羰基)脯胺酸衍生物 |
CN108250199B (zh) * | 2012-08-03 | 2021-07-16 | 百时美施贵宝公司 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
UY34959A (es) * | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
SI2906551T1 (en) | 2012-10-12 | 2018-05-31 | Bristol-Myers Squibb Company | CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR |
WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
WO2014120346A1 (en) | 2012-12-19 | 2014-08-07 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
CA2918814C (en) | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
US20160280688A1 (en) | 2013-09-26 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
US20160237044A1 (en) | 2013-09-26 | 2016-08-18 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
WO2015044172A1 (de) | 2013-09-26 | 2015-04-02 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate |
EP3049410A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate als faktor xia modulatoren |
US20160244437A1 (en) | 2013-09-26 | 2016-08-25 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
EP3049404A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate |
EP3049408A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate |
US20160272617A1 (en) | 2013-09-26 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
WO2015047973A1 (en) | 2013-09-27 | 2015-04-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
US20160257668A1 (en) | 2013-10-07 | 2016-09-08 | Merck Sharp & Dohme Corp. | Factor XIa Inhibitors |
JP6337750B2 (ja) | 2013-11-22 | 2018-06-06 | 小野薬品工業株式会社 | 化合物 |
AU2014378428A1 (en) | 2014-01-14 | 2016-09-01 | Sumitomo Dainippon Pharma Co., Ltd. | Condensed 5-oxazolidinone derivative |
NO2760821T3 (es) | 2014-01-31 | 2018-03-10 | ||
HUE040226T2 (hu) | 2014-01-31 | 2019-02-28 | Bristol Myers Squibb Co | Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként |
JP6382997B2 (ja) | 2014-02-07 | 2018-08-29 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
EP3104701B1 (en) | 2014-02-11 | 2019-01-30 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
US9944643B2 (en) | 2014-02-11 | 2018-04-17 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
EP3138839B1 (en) | 2014-02-14 | 2020-10-28 | Sichuan Haisco Pharmaceutical Co., Ltd. | Pyridone or pyrimidone derivative, preparation method therefor and application thereof |
PL3113772T3 (pl) | 2014-03-07 | 2021-04-06 | Biocryst Pharmaceuticals, Inc. | Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej |
US9808445B2 (en) | 2014-04-16 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
KR20150136294A (ko) | 2014-05-27 | 2015-12-07 | 주식회사 레고켐 바이오사이언스 | 인자 XIa 억제 활성을 가지는 신규한 화합물 |
JP2017517512A (ja) | 2014-05-28 | 2017-06-29 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 第xia因子インヒビター |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
NO2721243T3 (es) | 2014-10-01 | 2018-10-20 | ||
ES2814098T3 (es) | 2014-12-10 | 2021-03-26 | Ono Pharmaceutical Co | Derivado de dihidroindolizinona |
EP3310777B1 (en) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
-
2012
- 2012-08-31 NO NO12780535A patent/NO2760821T3/no unknown
-
2015
- 2015-01-30 PT PT157054271T patent/PT3099688T/pt unknown
- 2015-01-30 JP JP2016549270A patent/JP6419836B2/ja active Active
- 2015-01-30 WO PCT/US2015/013647 patent/WO2015116882A1/en active Application Filing
- 2015-01-30 HU HUE15705427A patent/HUE038060T2/hu unknown
- 2015-01-30 CA CA2937738A patent/CA2937738C/en active Active
- 2015-01-30 SI SI201530121T patent/SI3099688T1/sl unknown
- 2015-01-30 US US15/115,319 patent/US20170057961A1/en not_active Abandoned
- 2015-01-30 UY UY0001035972A patent/UY35972A/es active IP Right Grant
- 2015-01-30 LT LTEP15705427.1T patent/LT3099688T/lt unknown
- 2015-01-30 EA EA201691561A patent/EA032650B1/ru not_active IP Right Cessation
- 2015-01-30 AR ARP150100295A patent/AR099228A1/es unknown
- 2015-01-30 ES ES15705427.1T patent/ES2655540T3/es active Active
- 2015-01-30 BR BR112016016741-4A patent/BR112016016741B1/pt active IP Right Grant
- 2015-01-30 MX MX2016009385A patent/MX2016009385A/es active IP Right Grant
- 2015-01-30 RS RS20180033A patent/RS56785B1/sr unknown
- 2015-01-30 CN CN201580017759.3A patent/CN106459051B/zh active Active
- 2015-01-30 PL PL15705427T patent/PL3099688T3/pl unknown
- 2015-01-30 TW TW104103315A patent/TWI703144B/zh active
- 2015-01-30 EP EP15705427.1A patent/EP3099688B1/en active Active
- 2015-01-30 DK DK15705427.1T patent/DK3099688T3/en active
-
2017
- 2017-08-18 US US15/680,729 patent/US20170342071A1/en not_active Abandoned
- 2017-12-29 CY CY20171101357T patent/CY1120534T1/el unknown
- 2017-12-29 HR HRP20172002TT patent/HRP20172002T1/hr unknown
-
2018
- 2018-04-06 US US15/946,837 patent/US10273236B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CY1120534T1 (el) | 2019-07-10 |
JP2017504640A (ja) | 2017-02-09 |
LT3099688T (lt) | 2017-12-27 |
US20180222907A1 (en) | 2018-08-09 |
UY35972A (es) | 2015-07-31 |
US20170342071A1 (en) | 2017-11-30 |
EA201691561A1 (ru) | 2017-01-30 |
BR112016016741B1 (pt) | 2023-01-17 |
TWI703144B (zh) | 2020-09-01 |
JP6419836B2 (ja) | 2018-11-07 |
WO2015116882A1 (en) | 2015-08-06 |
BR112016016741A2 (es) | 2017-08-08 |
AR099228A1 (es) | 2016-07-06 |
EP3099688A1 (en) | 2016-12-07 |
CN106459051B (zh) | 2018-10-16 |
ES2655540T3 (es) | 2018-02-20 |
SI3099688T1 (sl) | 2017-12-29 |
US20170057961A1 (en) | 2017-03-02 |
PT3099688T (pt) | 2018-01-15 |
EA032650B1 (ru) | 2019-06-28 |
TW201615640A (zh) | 2016-05-01 |
PL3099688T3 (pl) | 2018-03-30 |
DK3099688T3 (en) | 2018-01-15 |
CA2937738C (en) | 2023-01-17 |
CA2937738A1 (en) | 2015-08-06 |
HRP20172002T1 (hr) | 2018-02-09 |
CN106459051A (zh) | 2017-02-22 |
RS56785B1 (sr) | 2018-04-30 |
US10273236B2 (en) | 2019-04-30 |
HUE038060T2 (hu) | 2018-09-28 |
EP3099688B1 (en) | 2017-10-18 |
NO2760821T3 (es) | 2018-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550418A1 (en) | Macrocycles with hetrocyclic p2` groups as factor xia inhibitors | |
PH12020500195A1 (en) | Pyrimidinones as factor xia inhibitors | |
MX2016009385A (es) | Inhibidores macrociclicos del factor xia condensados con heterociclicos. | |
MX2015000892A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
MX361370B (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
MX345763B (es) | Nuevos macrociclos como inhibidores del factor xia. | |
PH12015502248B1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
MX2012008874A (es) | Macrociclos como inhibidores del factor de coagulacion (fxia). | |
MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
MX2014004245A (es) | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia. | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |